HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

Lilly, Boehringer to slash at least $1B each from planned investments in Germany

In response to a planned healthcare reform initiative in Germany that would reduce the prices of branded drugs, Eli Lilly and Boehringer Ingelheim have slashed their planned investments in the country, each by at least $1 billion.

By FiercePharma · Jun 4, 2026 · via FiercePharma
Lilly, Boehringer to slash at least $1B each from planned investments in Germany

Image: FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
Alnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneer
The WeekFierceBiotech ↗
Alnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneer
Alnylam has partnered with the person who helped put the "T" in ChatGPT, paying $30 million to work with Jakob…
Jun 4, 2026
Revolution Medicines’ Pancreatic Cancer Drug Draws Early Expansion Buzz
The WeekBriefing
Revolution Medicines’ Pancreatic Cancer Drug Draws Early Expansion Buzz
Even before approval, Revolution Medicines’ pancreatic cancer asset is prompting discussion of how and when it…
Jun 4, 2026
STAT+: After hospitals, patients get a turn to bring AI into the doctor's office
The WeekSTAT News ↗
STAT+: After hospitals, patients get a turn to bring AI into the doctor's office
Ambient scribes were the first large-scale application of AI in health care. Now developers are pitching them …
Jun 4, 2026